Background: Aplastic anemia (AA) is rarely described after a diagnosis of autoimmune disease (aID). Aims: To assess the prevalence of prior aID in patients with AA recorded in the registry of the European Group for Blood and Marrow Transplantation (EBMT) and to evaluate treatment and outcome. Methods: 1,251 AA patients from 18 EBMT centers were assessed. Results: Fifty patients (4%) were eligible: 22 males and 28 females with a median age of 46 years at the diagnosis of aID and of 51 years at the diagnosis of AA. Information on the treatment of AA was available in 49 patients: 38 received only immunosuppressive therapy (IST), 8 patients underwent hematopoietic stem cell transplantation (HSCT) – 6 as first-line therapy and 2 after failure of IST – whilst 3 patients had a spontaneous recovery. After a median follow-up of 3.19 years, 32 patients were alive, including 7 of the 8 patients who underwent HSCT. Only 6 of 32 patients who were alive at the last follow-up were receiving IST for AA. Conclusions: Most cases of AA following aID benefitted from IST or HSCT if a matched donor was available. Further prospective investigation is needed to assess the effects of IST on the outcome of underlying aID.

1.
Young NS, Calado RT, Scheinberg P: Current concepts in the pathophysiology and treatment of aplastic anemia. Blood 2006;108:2509–2519.
2.
Cavalcant J, Shadduck RK, Winkelstein A, Zeigler Z, Mendelow H: Red-cell hypoplasia and increased bone marrow reticulin in systemic lupus erythematosus: reversal with corticosteroid therapy. Am J Hematol 1978;5:253–263.
3.
Stricker RB, Shuman MA: Aplastic anemia complicating systemic lupus erythematosus: response to androgens in two patients. Am J Hematol 1984;17:193–201.
4.
Bailey FA, Lilly M, Bertoli LF, Ball GV: An antibody that inhibits in vitro bone marrow proliferation in a patient with systemic lupus erythematosus and aplastic anemia. Arthritis Rheum 1989;32:901–905.
5.
Sumimoto S, Kawai M, Kasajima Y, Hamamoto T: Aplastic anemia associated with systemic lupus erythematosus. Am J Hematol 1991;38:329–331.
6.
Hinterberger-Fischer M, Kier P, Forstinger I, Lechner K, Kornek G, Breyer S, Ogris H, Pont J, Hinterberger W: Coincidence of severe aplastic anemia with multiple sclerosis or thyroid disorders. Report of 5 cases. Acta Haematol 1994;92:136–139.
7.
Satoh M, Yamagata H, Watanabe F, Matsushita Y, Nakayama S, Murakami M, Matsuyama J, Oshima S, Akizuki M: A case of Sjögren’s syndrome complicating immune-mediated aplastic anemia. Clin Rheumatol 1993;12:257–260.
8.
Matsumoto N, Kagawa H, Ichiyoshi H, Iguchi T, Yamanaka Y, Kishimoto Y, Fukuhara S: Aplastic anemia complicating Sjögren’s syndrome. Intern Med 1997;36:371–374.
9.
Diez S, Banias H, Diez-Martin JL, Briz M, Estrado J, Barcelò B: Apparent cure of Graves-Basedow disease after sibling allogeneic bone marrow transplantation. Clin Endocrinol 1999;50:267–270.
10.
Tomonari A, Tojo A, Iseki T, Ooi J, Hase H, Shirafuji N, Tani K, Asano S: Severe aplastic anemia with autoimmune thyroiditis showing no hematological response to intensive immunosuppressive therapy. Acta Haematol 2003;109:90–94.
11.
Lee WY, Oh ES, Min CK, Kim DW, Lee JW, Kang MI, Min WS, Cha BY, Lee KW, Son HY, Kang SK, Kim CC: Changes in autoimmune thyroid disease following allogeneic bone marrow transplantation. Bone Marrow Transplant 2001;28:63–66.
12.
Kumar M, Goldman J: Severe aplastic anaemia and Grave’s disease in a paediatric patient. Br J Haematol 2002;118:327–329.
13.
Singh NP, Prakash A, Garg D, Makhija A, Pathania A, Prakash N, Kubba S, Agarwal SK: Aplastic anemia complicating systemic lupus erythematosus: successful management with cyclosporine. Rheumatol Int 2004;24:40–42.
14.
Grey-Davies E, Hows JM, Marsh JC: Aplastic anaemia in association with coeliac disease: a series of three cases. Br J Haematol 2008;143:258–260.
15.
Stalder MP, Rovò A, Halter J, Heim D, Silzle T, Passweg J, Rischewski J, Stern M, Arber C, Buser A, Meyer-Monard S, Tichelli A, Gratwohl A: Aplastic anemia and concomitant autoimmune diseases. Ann Hematol 2009;88:659–665.
16.
Bacigalupo A: Guidelines for the treatment of severe aplastic anemia. Working Party on Severe Aplastic Anemia (WPSAA) of the European Group of Bone Marrow Transplantation (EBMT). Haematologica 1994;79:438–444.
17.
Camitta BM: What is the definition of cure for aplastic anemia? Acta Haematol 2000;103:16–18.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.